Haemonetics Corporation Releases Financial Results for Q3 of Fiscal Year 2026

On February 5, 2026, Haemonetics Corporation, a leading global medical technology company, announced its financial results for the third quarter of fiscal year 2026, which concluded on December 27, 2025. The results have been made accessible on the company's Investor Relations website, showcasing their ongoing commitment to transparency and investor engagement.

Financial Performance Highlights

During this quarter, Haemonetics has demonstrated robust financial performance, marking significant milestones compared to previous quarters. The earnings release features a comprehensive overview of the company's financial health, detailing aspects such as revenue growth, profitability, and strategic initiatives that have contributed to their success. Investors and analysts are encouraged to review these results as the company continues to position itself for future growth.

Earnings Conference Call

To further engage with investors and analysts, Haemonetics will host a conference call and live webcast at 8:00 a.m. ET on February 5, 2026. This call presents an opportunity for stakeholders to gain deeper insights into the financial results, as well as to ask questions directly to the management team. Registration for the call can be completed through their Investor Relations website. Participants will receive personalized access details upon completing the registration.

Supplementary Materials

In support of the earnings call, Haemonetics has made additional materials available, including a detailed earnings release and a supplemental presentation outlining the key performance indicators for the third quarter. These documents will provide investors with valuable context and enhance their understanding of the company’s strategic direction and operational performance.

About Haemonetics Corporation

Established as a pioneer in medical technology, Haemonetics focuses on enhancing health care quality and effectiveness. Their offerings include innovative solutions tailored to meet critical medical needs. These encompass hospital technologies designed to elevate care standards and improve patient outcomes, state-of-the-art plasma collection systems that streamline operations, and products aimed at bolstering blood collection services across various healthcare sectors.

For those looking to delve deeper into the company’s innovative solutions and overall mission, the Haemonetics website serves as a valuable resource. Here, stakeholders can explore the full range of products and services that exemplify Haemonetics' commitment to advancing health care.

Conclusion

As the company prepares for its conference call and continues to unveil innovative medical technology solutions, the release of their third quarter financial results marks a pivotal moment for Haemonetics Corporation. This quarter's performance not only highlights their strong fiscal standing but also sets the stage for sustained growth in the increasingly competitive health care market.

For further information, contact the Investor Relations team or visit www.haemonetics.com.